WuXi Biologics Achieves Full-Scale Manufacturing Milestone at Ireland Facility
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
HitGen Inc. and Bostal Drug Delivery Form Strategic Partnership to Advance Nucleic Acid Drug Development
HitGen Inc. (SHA: 688222), a China-based company, has announced a strategic partnership with Bostal Drug...
Novartis and Fudan University Shanghai Cancer Center Renew Partnership to Drive Precision Cancer Treatments
Novartis (NYSE: NVS), the Swiss pharmaceutical colossus, has renewed its memorandum of understanding with Fudan...
Rebecca Tech Secures USD 10 Million in Series A++ Funding to Expand Micro RF Technology Globally
Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the...
Jiangsu Hengrui Receives Chinese Approval for First Domestic Category 1 Opioid Analgesic for Postoperative Pain
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has proclaimed the receipt of marketing approval in...
Acotec Scientific’s Peridge Catheter Receives NMPA Nod for Hemodialysis Lesion Treatment
Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it...
Beijing Tiantan Biological Halts Phase III Clinical Trial for CMV Immunoglobulin Citing Strategic Reasons
Beijing Tiantan Biological Products Co., Ltd (SHA: 600161), a biopharmaceutical firm based in China, has...
WuXi XDC Forecasts Over 100% Revenue Growth for 2023 on Strength of ADC Industry
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKEX: 2269) and WuXi STA,...
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth...
Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales...
Gilead’s Kite Subsidiary Reduces CAR T-Cell Therapy Turnaround Time with FDA Approval
Kite, a subsidiary of Gilead (NASDAQ: GILD), has announced a significant enhancement in the treatment...
Junde Pharmaceuticals Licenses Weight-Reducing Capsule JTX-102 to Changchun GeneScience
Xiamen Junde Pharmaceutical Technology Co., Ltd., a China-based pharmaceutical company, has entered into a licensing...
Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens
Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing...
Kangtai Biological Products Co., Ltd. Expands Vaccine Access in South Asia with Bangladesh Deal
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a Chinese biopharmaceutical firm, has announced the...
Smartnuclide Biopharmaceutical Partners with Gosun Pharmaceuticals for rhTSH Market Promotion in China
Suzhou Smartnuclide Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has entered into a business cooperation...
MindRank Ltd Partners with Henlius Biotech to Pioneer AI-Powered Drug Therapies
MindRank Ltd, a China-based frontier in AI-enabled drug development, has inked a strategic partnership with...
Sandoz Launches Biosimilar Natalizumab in Germany, Challenging Biogen’s Tysabri
Sandoz, a division of Novartis and a leader in generic drugs and biosimilars headquartered in...
Siemens Healthineers AG and Shandong First Medical University’s College of Radiology Collaborate on Medical Imaging Metaverse
Siemens Healthineers AG (ETR: SHL), a leading life sciences company based in Germany, has entered...
Clinigen Expands Global Footprint with First Fully-Owned Subsidiary in Shanghai’s Free Trade Zone
Clinigen, a UK-based medical and pharmaceutical services provider, has announced the establishment of its first...
European Commission Approves Takeda’s Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy
The European Commission (EC) has granted regulatory approval to Takeda Pharmaceutical Company Limited (TYO: 4502)...